FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

FBLG FibroBiologics

交易中 05-08 10:02:28 EDT

1.24

+0.00

0.00%

最高1.24	最低1.21	成交量2.24万
今开1.23	昨收1.24	日振幅2.41%
总市值645.91万	流通市值350.65万	总股本520.89万
成交额2.76万	换手率0.79%	流通股本282.78万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":1.24,"timestamp":1778248939928,"preClose":1.24,"halted":0,"volume":22397,"delay":0,"changeRate":0,"floatShares":2827825,"shares":5208915,"eps":-6.878533,"marketStatus":"交易中","change":0,"latestTime":"05-08 10:02:28 EDT","open":1.23,"high":1.24,"low":1.2101,"amount":27641.2485912,"amplitude":0.024113,"askPrice":1.27,"askSize":373,"bidPrice":1.23,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-6.878533,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778270400000},"marketStatusCode":2,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":1.24,"preHourTrading":{"tag":"盘前","latestPrice":1.25,"preClose":1.24,"latestTime":"09:28 EDT","volume":351,"amount":439.9059483,"timestamp":1778246880047,"change":0.01,"changeRate":0.008065,"amplitude":0.056452},"postHourTrading":{"tag":"盘后","latestPrice":1.2387,"preClose":1.24,"latestTime":"19:55 EDT","volume":1531,"amount":1905.5225,"timestamp":1778198108854,"change":-0.0013,"changeRate":-0.001048,"amplitude":0.017177},"volumeRatio":0.533686},"requestUrl":"/m/hq/s/FBLG","defaultTab":"news","newsList":[{"id":"1131452413","title":"FibroBiologics启动1/2期临床试验 评估CYWc628对糖尿病足溃疡患者的安全性、耐受性及疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1131452413","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131452413?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:31","pubTimestamp":1777897876,"startTime":"0","endTime":"0","summary":"生物技术公司FibroBiologics宣布，将开展一项针对糖尿病足溃疡患者的1/2期临床研究。该试验旨在系统评估候选药物CYWc628在患者群体中的安全性表现、耐受性水平以及潜在治疗效果。\n这项临床研究的推进，标志着FibroBiologics在细胞疗法领域取得了新的阶段性进展。通过严谨的临床试验设计，公司期望为糖尿病足溃疡这一难治性疾病的治疗提供新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170332450","title":"FibroBiologics宣布Cywc628药物产品完成生产 将用于糖尿病足溃疡1/2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1170332450","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170332450?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:30","pubTimestamp":1777897838,"startTime":"0","endTime":"0","summary":"生物技术公司FibroBiologics正式宣布，其针对糖尿病足溃疡治疗的核心候选药物Cywc628已完成生产放行流程。该批药物将立即投入即将启动的1/2期临床试验阶段，标志着公司在纤维细胞疗法领域取得关键进展。\n此次药物放行严格遵循药品生产质量管理规范，确保临床试验用药的安全性与稳定性。糖尿病足溃疡作为糖尿病最常见的严重并发症之一，目前临床治疗手段有限，Cywc628的推进将为患者提供潜在的新型治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156447376","title":"FibroBiologics达成ATM发行协议 拟发售最高615万美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1156447376","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156447376?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:04","pubTimestamp":1777665867,"startTime":"0","endTime":"0","summary":"再生医学公司FibroBiologics（股票代码：FBLG）近日向美国证券交易委员会（SEC）提交文件，宣布已签订一项市场发行（ATM）协议。根据该协议，公司获权通过承销商发售价值最高达615万美元的普通股。\nATM发行机制允许上市公司根据市场情况灵活择机发售新股，此举将为FibroBiologics提供额外的运营资金。该公司专注于利用成纤维细胞技术开发慢性疾病创新疗法，此次融资将加速其细胞疗法管线的临床推进。\n此次发行具体条款将取决于市场条件、股价波动及公司资金需求等因素。通过这种股权融资方式，FibroBiologics有望在保持资金灵活性的同时，为长期研发投入提供支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125810558","title":"FibroBiologics与United Fire & Casualty签订租约终止协议，生效日期为2026年4月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=1125810558","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125810558?lang=zh_cn&edition=full","pubTime":"2026-04-10 04:22","pubTimestamp":1775766154,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会（SEC）提交的文件，FibroBiologics公司已与United Fire & Casualty达成一项租约终止协议，该协议将于2026年4月3日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128604799","title":"FibroBiologics宣布成功生产Cywc628药物产品，为即将开展的糖尿病足溃疡临床试验提供支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1128604799","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128604799?lang=zh_cn&edition=full","pubTime":"2026-04-01 04:16","pubTimestamp":1774988194,"startTime":"0","endTime":"0","summary":"FibroBiologics公司近日宣布，已成功完成Cywc628药物产品的生产工作，该产品将用于支持即将启动的糖尿病足溃疡临床试验。这一进展标志着公司在细胞纤维化治疗领域迈出重要一步，也为后续临床研究奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150891053","title":"FibroBiologics宣布实施合股计划，旨在重新符合纳斯达克最低买入价规定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150891053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150891053?lang=zh_cn&edition=full","pubTime":"2026-03-26 04:31","pubTimestamp":1774470675,"startTime":"0","endTime":"0","summary":"FibroBiologics（股票代码：FBLG）近日公布一项重要举措，公司将进行反向股票分割（reverse stock split），以恢复对纳斯达克交易所最低买入价要求的合规状态。此举旨在通过调整流通股数量，提升每股市场交易价格，从而满足交易所持续上市标准中关于股价的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618873861","title":"Fibrobiologics, Inc.盘中异动 早盘急速下跌5.30%报0.375美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618873861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618873861?lang=zh_cn&edition=full","pubTime":"2026-03-11 22:29","pubTimestamp":1773239341,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日22时29分，Fibrobiologics, Inc.股票出现波动，股价大幅下挫5.30%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.49%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122290197addcdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122290197addcdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617578712","title":"Fibrobiologics, Inc.盘中异动 大幅上涨5.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617578712","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617578712?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:33","pubTimestamp":1772721185,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时33分，Fibrobiologics, Inc.股票出现波动，股价急速上涨5.94%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.66%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030522330695432e4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030522330695432e4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","IBO","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180594991","title":"FibroBiologics完成针对难治性糖尿病足溃疡的Cywc628一期/二期临床试验中心启动工作","url":"https://stock-news.laohu8.com/highlight/detail?id=1180594991","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180594991?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:31","pubTimestamp":1772717517,"startTime":"0","endTime":"0","summary":"生物技术公司FibroBiologics已顺利完成针对候选药物Cywc628的一期/二期临床试验中心启动流程。该试验旨在评估Cywc628在治疗难治性糖尿病足溃疡方面的安全性与有效性。这一关键进展为后续患者入组及临床研究开展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159497620","title":"FibroBiologics公司宣布获得美国专利，涵盖用于治疗骨质疏松的成纤维细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1159497620","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159497620?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:33","pubTimestamp":1772458424,"startTime":"0","endTime":"0","summary":"FibroBiologics公司近日宣布，其针对骨质疏松症治疗的成纤维细胞疗法已获得美国专利授权。这一专利的授予标志着该公司在细胞治疗领域，特别是在骨骼疾病治疗方向取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612463025","title":"Fibrobiologics, Inc.盘中异动 早盘快速拉升5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463025","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612463025?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:30","pubTimestamp":1771338639,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日22时30分，Fibrobiologics, Inc.股票出现波动，股价快速上涨5.34%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021722303997a6669e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021722303997a6669e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611979289","title":"Fibrobiologics, Inc.盘中异动 早盘股价大跌5.58%报0.241美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611979289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611979289?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:11","pubTimestamp":1770912688,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时11分，Fibrobiologics, Inc.股票出现异动，股价大幅下挫5.58%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.61%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602130011289540f00a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602130011289540f00a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601814747","title":"Fibrobiologics, Inc.盘中异动 快速上涨5.05%报0.256美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601814747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601814747?lang=zh_cn&edition=full","pubTime":"2026-01-07 00:32","pubTimestamp":1767717138,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日00时32分，Fibrobiologics, Inc.股票出现波动，股价快速上涨5.05%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107003219953c190e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107003219953c190e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185969009","title":"FibroBiologics公布成纤维细胞球源性软骨细胞球疗法治疗退行性椎间盘疾病的积极临床前结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1185969009","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185969009?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:30","pubTimestamp":1767619821,"startTime":"0","endTime":"0","summary":"FibroBiologics（股票代码：FBLG）近日宣布，其针对退行性椎间盘疾病研发的成纤维细胞球源性软骨细胞（Fsdc）球疗法在临床前研究中取得积极成果。该疗法展现出了良好的治疗潜力，为后续的临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126005925","title":"FibroBiologics向美国FDA提交新药临床试验申请 推进Cyps317治疗银屑病临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1126005925","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126005925?lang=zh_cn&edition=full","pubTime":"2025-12-31 21:31","pubTimestamp":1767187874,"startTime":"0","endTime":"0","summary":"FibroBiologics已正式向美国食品药品监督管理局提交新药临床试验申请，旨在加速其候选药物Cyps317在银屑病患者中的临床开发进程。这一重要监管步骤标志着该疗法向临床应用迈出了关键一步，为后续临床试验的开展铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594594244","title":"Fibrobiologics, Inc.盘中异动 大幅上涨5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594594244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594594244?lang=zh_cn&edition=full","pubTime":"2025-12-27 05:00","pubTimestamp":1766782810,"startTime":"0","endTime":"0","summary":"北京时间2025年12月27日05时00分，Fibrobiologics, Inc.股票出现波动，股价大幅上涨5.55%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227050011a47cdae1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227050011a47cdae1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170596843","title":"FibroBiologics宣布以市场价格进行170万美元的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1170596843","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170596843?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:04","pubTimestamp":1765803862,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布以市场价格进行170万美元的注册直接发行，符合纳斯达克的相关规则。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190833209","title":"FibroBiologics Inc - 全部清偿对Ya Ii Pn, Ltd. 发行的可转换票据的未偿还金额","url":"https://stock-news.laohu8.com/highlight/detail?id=1190833209","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190833209?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:33","pubTimestamp":1764164015,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc - 全部清偿对Ya Ii Pn, Ltd. 发行的可转换票据的未偿还金额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111063136","title":"FibroBiologics完成150万美元的直接注册发行，定价符合纳斯达克规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1111063136","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111063136?lang=zh_cn&edition=full","pubTime":"2025-11-26 05:05","pubTimestamp":1764104737,"startTime":"0","endTime":"0","summary":"FibroBiologics完成150万美元的直接注册发行，定价符合纳斯达克规则","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586024344","title":"Fibrobiologics, Inc.盘中异动 股价大涨5.31%报0.274美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586024344","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586024344?lang=zh_cn&edition=full","pubTime":"2025-11-26 01:01","pubTimestamp":1764090067,"startTime":"0","endTime":"0","summary":"北京时间2025年11月26日01时01分，Fibrobiologics, Inc.股票出现波动，股价急速上涨5.31%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126010107977efa9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126010107977efa9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fibrobiologics.com","stockEarnings":[{"period":"1week","weight":-0.0606},{"period":"1month","weight":-0.1268},{"period":"3month","weight":-0.7537},{"period":"6month","weight":-0.8241},{"period":"1year","weight":-0.9315},{"period":"ytd","weight":-0.7243}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"FibroBiologics, Inc.最初于2021年4月8日根据德克萨斯州法律成立为有限责任公司，然后于2021年12月14日转变为特拉华州公司。FibroBiologics是一家早期细胞治疗公司，总部位于德克萨斯州休斯顿，开发利用成纤维细胞治疗慢性疾病的创新疗法。该公司的主要重点是启动和推进与成纤维细胞治疗退行性椎间盘疾病、多发性硬化症、癌症、伤口愈合和其他疾病相关的临床前研究和临床阶段FDA试验。","exchange":"NASDAQ","name":"FibroBiologics","nameEN":"FibroBiologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供FibroBiologics(FBLG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"FibroBiologics,FBLG,FibroBiologics股票,FibroBiologics股票老虎,FibroBiologics股票老虎国际,FibroBiologics行情,FibroBiologics股票行情,FibroBiologics股价,FibroBiologics股市,FibroBiologics股票价格,FibroBiologics股票交易,FibroBiologics股票购买,FibroBiologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供FibroBiologics(FBLG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}